BMS BUYS RIGHTS TO PRM-151 AND PROMEDIOR
MPNRF | August 31, 2015
August 31, 2015
Bristol-Myers Squibb has bought rights to a fibrosis drug and its privately held developer – Promedior. The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested in myelofibrosis as well as diopathic pulmonary fibrosis.
Promedior’s mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.